San-Miguel J, Hungria VTM, Yoon S, et al. Panobinostat plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma who received prior bortezomib and IMiDs: a predefined subgroup analysis of PANORAMA 1. Presented at: ASCO 2015; May 29-June 2, 2015; Chicago, IL.
The link you have chosen leads to a site maintained by a third party over whom pharma& has no control. As such, pharma& makes no representation as to the accuracy or any other aspect of the information on this site.
This is an international site for FARYDAK® (panobinostat) and is intended for health care professionals (HCPs) outside the United States. The information on the site is not country-specific and may contain information that is outside the approved indication for the country in which you are located. Please contact your local Secura Bio representative for the local prescribing information specific to your country.
Welcome to the FARYDAK® (panobinostat) Product Website
FARYDAK is approved for use in 34 countries around the world.
FARYDAK Country-level Websites
Below is a list of the countries that host a FARYDAK website based on a local label and local language. They are intended for health care professionals (HCPs) only. If you are an HCP from one of the countries listed below, click on your country link to be redirected to your country’s FARYDAK website.
United States — Farydak® has been discontinued in the United States
FARYDAK International Website
This website is intended for health care professionals (HCPs) outside the United States. The information on this website is not country-specific and may contain information that is outside the approved indication for the country in which you are located. Please contact your local Secura Bio representative for local prescribing information via https://securabio.com.
IMPORTANT: The information on this website is based on the European Summary of Product Characteristics (EU SmPC).
